Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

rscheringpharma.de .

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the initiation of clinical trials, regulatory plans and expected timelines for alemtuzumab, including the initiation of a second Phase 3 trial in MS patients and the timing thereof, the timing of obtaining clinical trial data, enrollment in clinical trials and the ability to manage patient safety. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: that final results of the clinical trial demonstrate safety and efficacy comparable to the interim data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements

Genzyme(R), Campath(R), and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved. Rebif(R) is a registered trademark of EMD Serono, Inc.<
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)... -- Boston Scientific Corporation (NYSE: BSX ) ... Annual Healthcare Conference on Tuesday, November 11, 2014 in ... , executive vice president and chief financial officer, will ... 8:00 a.m. PT followed by a question and answer ... and question and answer session will be available to ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... is scheduled to present at the 23rd Annual Piper Jaffray ... and 30th at The New York Palace in New York ... on December 1, 2011 at Island Shangri-La Hotel, Hong Kong. ...
... (Nasdaq: ISIS ), the leader in antisense therapeutics, ... Piper Jaffray,s Health Care Conference on Wednesday, November ... Palace. A live audio webcast of the presentation ... the Company,s Web site, www.isispharm.com . A replay of ...
Cached Medicine Technology:Sinovac to Present at 23rd Annual Piper Jaffray Health Care Conference and HK/China Mini Conference 2011 (Healthcare) 2
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, ... genes have been identified that appear linked to autism ... say they are on their way to discovering up ... disorder. Autism spectrum disorders include a range of ... repetitive behaviors. An estimated one in 68 U.S. children ...
(Date:10/30/2014)... FL (PRWEB) October 30, 2014 ... offering therapeutic horseback riding to special needs individuals in ... Round-Up on Saturday, November 15 from 10-2:00 p.m. at ... event is open to the public and is designed ... , Admission to the HSS Round-Up is free. ...
(Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- When it comes ... likely than men to delay care when they have symptoms ... someone comes to the hospital with a more severe or ... options available," study author Catherine Kreatsoulas, a Fulbright Scholar and ... in a news release from the Heart and Stroke Foundation ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Many ... near campus, even though tanning increases the risk ... popular among young adults, particularly white women, so ... students, health, the researchers said. "Public health ... student population awareness of the harms that indoor ...
Breaking Medicine News(10 mins):Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... A University of Missouri researcher has found that ... increases satiety and reduces hunger throughout the day. In ... found that eating a protein-rich breakfast reduces the brain ... "Everyone knows that eating breakfast is important, but many ...
... reduced inflammation in Crohn,s patients in a research ... Crohn,s disease is a chronic inflammatory condition of ... bleeding and weight loss. Treatments for Crohn,s disease ... be associated with rare but serious side effects, ...
... studies on whether moderate exercise can curb the nicotine ... apparent contradiction: it seems to work in short-term, well ... trials. A new study may explain why and help ... in the results of research led by David Williams, ...
... little more difficult now that French researchers have discovered ... seriously compromised during long-term space flight. In a new ... ( http://www.fasebj.org ), the scientists show that antibodies produced ... terra firma. The reduced effectiveness of antibodies makes astronauts ...
... is a major problem for society behind only headaches as ... degeneration of the intervertebral disc. Researchers have worked for many ... on the lower back. Now, in results published in ... permanently replace the workings of the invertebral disc. It is ...
... , THURSDAY, May 19 (HealthDay News) -- Problem ... availability, especially online, of gambling opportunities, said experts who ... of the disorder. While most people gamble as ... become too seriously involved in terms of time invested ...
Cached Medicine News:Health News:Eat a protein-rich breakfast to reduce food cravings, prevent overeating later, researcher finds 2Health News:Use of naltrexone reduces inflammation in Crohn's patients 2Health News:Exercise helps women fight smoking cravings, but effect is short-lived 2Health News:Antibody production gets confused during long-term spaceflight 2Health News:Implant jab could solve the misery of back pain 2Health News:Internet Is Playing a Part in Spread of Problem Gambling 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: